

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Juha-Matti SAVOLA et al.

Serial Number: 10/534,091

Group Art Unit: 1618

Filing Date: May 6, 2005

Examiner: Gembeh, Shirley V.

For: OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME

DECLARATION PURSUANT TO 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Juha-Matti SAVOLA, hereby declare as follows:

1. I am one of the co-inventors of the invention disclosed and claimed in this application.

2. I have postgraduate educational training in medicine and pharmacology and a quarter century of research and management experience in medicine, pharmacology, and preclinical and clinical trial design and execution.

a) I received my MD in 1983 from the University of Oulu, Finland, my PhD in 1986 in Pharmacology from the University of Oulu, Finland, and was nominated as an Associate Professor (Docent in Drug Discovery) in 1997 by the University of Turku, Finland.

- b) From 1983 - 1988, I was engaged in setting up an extensive selection of in vivo and in vitro models in the field of cardiovascular and CNS pharmacology at Oulu University, Finland.
- c) From August 1988 - November 1989, I was a Postdoctoral Fellow at Stanford University and the University of California, San Francisco (UCSF), performing research in the molecular and biochemical pharmacology of the adrenergic alpha-2 and beta receptors, including their hormonal regulation at the receptor protein expression and mRNA and DNA levels.
- d) Thereafter, from November 1989 through January 1992, I was a Research Scientist, then Laboratory Head, at Farnos Research, Farnos Group Ltd., Finland. In this role, I established a G-protein coupled receptor (GPCR) screening function to support drug discovery efforts.
- e) From January 1992 through August 1997 I was Head of the Department for Drug Design and Screening, at the Orion Corporation, Finland, responsible for computational and pharmacological drug discovery functions of Orion Pharma (excluding those related to the cancer drug discovery).

- f) For 9 years, starting August 1997, I was CEO at Juvantia Pharma Ltd., Finland. At Juvantia, I was responsible for designing preclinical and clinical development strategies for fipamezole for treatment of movement disorders in advanced Parkinson's disease. During this time, I contributed to developing fipamezole from "napkin chemistry" to first-in-man studies in two years, reformulating the product, and moving the compound into phase 2a proof-of-concept study in two additional years. During this time, Juvantia conducted clinical studies in Finland, the UK and the US.
- g) I am currently Vice President of Development, Fipamezole, at Santhera Pharmaceuticals (Switzerland) Ltd., to which Juvantia licensed fipamezole during my tenure as Juvantia CEO. (Santhera is the current owner of this application.) In this capacity, I continue to oversee as program director design of preclinical and clinical development strategies and building development plans for fipamezole as a therapeutic agent in Parkinson's disease. In particular, I have responsibility for designing and providing medical expertise to the clinical study

protocols and other clinical trial documents [Informed Consent Forms (ICFs), Case Report Forms (CRFs), statistical analysis plans, reports and publications], to the investigator's brochure, Investigational Medicinal Product Dossier (IMPD) and the Investigational New Drug (IND) updates, and to clinical study data analysis and interpretation.

- h) I am the author of 47 peer-reviewed scientific papers.
- i) My curriculum vitae is attached.

3. I have read the Declaration of Dr. Jürg P. Seiler, filed December 30, 2009, and its Appendices, notably Appendix II, and I agree with its factual assertions and its scientific conclusions.

4. I have also read the Official Action mailed February 25, 2010 ("Official Action"), and do not agree with its factual assertions and scientific conclusions. In this Declaration, I address the scientific and medical errors underlying the Examiner's rejections.

QTc Prolongation Is Independent from Heart Rate

5. The Examiner's statement that "QTc is associated with heart rate" (Official Action, page 5, line 4) is incorrect.

6. The QT interval of an electrocardiogram (the time from the beginning of the QRS complex to the end of the T wave) is a measure of the duration of ventricular depolarization and repolarization. See "The QT-Interval in the Electrocardiogram" beginning on page 3 of Appendix II of Dr. Seiler's Declaration filed December 30, 2009.

7. As commonly known, in a normally functioning heart the QT interval has an inverse relationship to heart rate (the faster the heart rate, the shorter the QT interval). Because heart rate varies widely within an individual from time to time, for assessment purposes the measured QT interval must be corrected by means of one of several-commonly used formulae to a heart rate-independent value, QTc. In short, QTc is the QT interval corrected for heart rate.

8. QTc prolongation is independent from heart rate, and can occur even though heart rate remains unchanged. See paragraph 12 of Dr. Seiler's Declaration.

9. In my opinion, nothing concerning QTc prolongation or the absence thereof can be determined or predicted from the heart rate value (or from a change in heart rate) upon administration of a drug.

**One of ordinary skill Cannot Predict Whether
Oromucosal Administration of Fipamezole Will
or Will Not Prolong QTc From Huupponen**

10. The Patent Office argument that Huupponen et al., 58 Clin.Pharmacol.Ther. 506-11 (1995) ("Huupponen") suggests fipamezole can be oromucosally administered without prolonging the QTc interval is incorrect.

11. Huupponen teaches oromucosal administration of atipamezole (a fipamezole analog) increases its bioavailability in comparison to oral administration. However, Huupponen fails to disclose anything about atipamezole's effect, if any, on QT interval or its prolongation. In this regard, the Examiner argues

[s]ince QTc is associated with heart rate and the rate of the heart is unchanged [in Huupponen], it is therefore reasonable that there is no prolongation of QTc was evident (see entire document).

Official Action, p. 5, lines 4 - 6. There can be nothing "reasonable" about the Examiner's QTc inference because it is based on a mistaken belief that QTc is associated with heart rate. In fact, Huupponen's disclosure that oromucosal administration of atipamezole did not change heart rate is meaningless with respect to QTc prolongation because QT prolongation can be induced at unchanged heart rate, and because QTc is a value corrected for changes in, and thus independent from, heart rate.

12. In my opinion, one of ordinary skill in the art would not assume anything from Huupponen regarding the presence or absence of QTc prolongation upon oromucosal administration of atipamezole because nothing concerning QTc prolongation or the absence thereof can be determined or predicted from heart rate. Moreover, nothing can be predicted regarding the presence or absence of QTc prolongation due to oromucosal administration of fipamezole, an atipamezole analog as to which Huupponen is completely silent.

**Those of Ordinary Skill Will Abandon A Drug Candidate
which Prolongs QTc**

13. The delay in cardiac repolarization caused by QTc prolongation creates an environment which favors ventricular arrhythmias. One of these ventricular arrhythmias is called "Torsade de Pointes", an arrhythmia which can be fatal.

14. QTc prolongation is evaluated as early as possible in the research and development of a new drug molecule precisely because of the risk of fatal arrhythmias. In my opinion, the dosages used are irrelevant because pharmaceutical industry practice is to abandon all further development of a drug molecule which prolongs the QTc interval - at any dose - due to the risk of fatal arrhythmias such as Torsade de Pointes.

**The Dog Toxicity Data Can Be Extrapolated
to Clinical Dosages**

15. International guidelines on how to properly assess a drug's tendency to prolong the QT interval include the recording of cardiac conductivity as electrocardiograms from conscious dogs which have been administered the drug under investigation at

various doses, including multiples of the anticipated human exposure to the drug in the clinic.

16. The dog toxicity studies performed with fipamezole (Application Example 8) show that *oral* administration causes QTc prolongation¹, with the prolongation increasing with increasing fipamezole plasma concentration once the systemic concentration in blood exceeds a certain threshold.

17. As further reported in Example 8, we demonstrated that *oromucosal* administration, remarkably, does not cause QTc prolongation at the relevant plasma concentrations, i.e., the concentrations at which QTc prolongation had been observed upon *oral* administration. For purposes of this second study, the only relevance of dosage was to ensure plasma concentrations equal to and greater than those that cause QTc prolongation upon *oral* administration, in order to permit direct comparison of the relative propensity of the drug to cause QTc prolongation by these two different routes of administration.

¹Although the specification states that uncorrected "QT prolongation was observed", corrected QTc values were also prolonged at those plasma concentrations.

18. In my opinion, one of ordinary skill in the art would extrapolate the QTc data generated in the dog toxicity studies to the clinical situation. More particularly, one of ordinary skill would believe oromucosal administration of fipamezole would not prolong the QTc interval at any clinical dose in view of (1) the absence of QTc prolongation at higher-than-clinical dosages when oromucosally administered to the dog, and (2) the dose-dependent nature of QTc prolongation caused by oral administration of fipamezole.


19. All statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true. These statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

U.S. Patent Appln. S.N. 10/534,091
DECLARATION PURSUANT TO 37 C.F.R. § 1.132

PATENT

States Code, and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Signed this 25th day of May, 2010.



Juha-Matti Savola

Enclosure:

Curriculum vitae of Juha-Matti Savola

Curriculum Vitae

Name Juha Savola

E-mail juhamatti.savola@gmail.com

Home Address Rainenweg 130
CH-4135 Reinach BL
Switzerland

Telephone +41 79 460 95 93 (work)

Date of Birth January 28th, 1958

Nationality Finnish

Civil status Married

Resident Switzerland, Reinach (BL)

Permit status B

Education MD, PhD
University of Oulu, Finland

Current Position VP Development Fipamezole
Santhera Pharmaceuticals (Switzerland) Ltd.
CH-4410 Liestal, Switzerland



Relevant work experience:

Since 2006 (3 years) at current position providing successful clinical and preclinical program development and execution in the leading role;
9 years CEO and head of clinical development at Juvantia Pharma Ltd.

Languages Good written and spoken English, intermediate in written German

Computer skills Very good (MS Office, Project, Access, PSNext)

Professional Experience

8.2006-present **Director Clinical Development / VP Development Fipamezole, Santhera, Switzerland**

- Indications: Parkinson's disease, neurogenic orthostatic hypotension
- Program director
 - Designing preclinical and clinical development strategies and building development plans with reporting and budget responsibility
 - Building and leading the cross-functional matrix development team with global responsibility for all development aspects (non-clinical, technical and clinical phases 1 to 3)
 - Designing and providing medical expertise to the clinical study protocols and other clinical trial documents (ICFs, CRF, statistical analysis plans, reports and publications), to the investigator's brochure, IMPD and the IND updates, and to clinical study data analysis and interpretation
 - Developing contents and presentation materials for advisory boards, investigator meetings and for the training of monitors and CRAs

- FJORD (US, India) and FOEHN (France, Portugal) phase 2 studies
- Medical expertise with internal (MT, BOD) and external (health authorities, KOLs and investigators) stakeholders
- Leadership in establishing and maintaining contacts with the clinical community, KOLs and investigators
- Interfacing with drug safety/pharmacovigilance and regulatory functions
- Supporting business development activities
- Member of the Clinical Science Team of Santhera and the Scientific Committee of the Fjord Study

1997-2006

Chief Executive Officer, heading drug development, Juvantia Pharma Ltd., Finland

- Indications: Parkinson's disease, chronic pain, schizophrenia, vasoconstrictive disorders
- Planning for the strategic and operative activities of the company, including fundraising and execution of the exit plan, setting up the most advanced high-throughput drug discovery unit in Finland at the time (combination of the efforts of computational chemistry, high-throughput organic chemistry and pharmacological testing) and clinical operations and establishing business development and other administrative corporate functions
 - Building a portfolio of fipamezole, novel non-peptidic somatostatin SST_{1/4} subtype selective agents for chronic pain and inflammatory diseases, alpha-2C selective antagonists for treatment of depression and schizophrenia and alpha-2B antagonist for treatment of vasoconstrictive disorders
 - Development and implementation of product positioning strategies
 - Establishing and maintaining a strong IPR portfolio to support the product concepts
 - Establishing licensing agreements with Orion Corporation and two major leading international pharmaceutical companies
 - Initiating and leading the fipamezole licensing deal arrangement with Santhera
- Designing preclinical and clinical development strategies and building the development plan for fipamezole in treatment of movement disorders in advanced Parkinson's disease
 - Developing fipamezole from napkin chemistry to first-in-man studies in two years, reformulated the product and got into phase 2a proof-of-concept study in two additional years
 - Conducting the clinical studies in Finland, the UK and the US under the FDA IND and regulatory approval process of the national health authorities

1993-1997

Department Head, Drug Design and Screening, Orion Corporation Orion Pharma, Finland

- Responsible for the operative functions with budget responsibilities of the computational and pharmacological drug discovery functions of Orion Pharma (excluding those related to the cancer drug discovery), the units being located in the Espoo, Helsinki and Turku regions

1989-1992

Research Scientist/Laboratory Head, Farnos Research, Farnos Group Ltd., Finland

- Setting up a GPCR screening function to support drug discovery

1988-1989 **Postdoctoral Fellow, Department of Anesthesia, Stanford University, and Reproductive Endocrinology Center, Department of Obstetrics and Gynecology, UCSF, USA**

- Molecular and biochemical pharmacology of the adrenergic alpha-2 and beta receptors, including their hormonal regulation at the receptor quantity/mRNA and DNA level, receptor cross-talk

1983-1988 **Research Scientist with teaching duties, Oulu University, Finland**

- Setting up an extensive selection of *in vivo* and *in vitro* models in the field of cardiovascular and CNS pharmacology

Membership in Professional Societies

- Society for Neuroscience
- Movement Disorder Society

Publications

- An author to 47 peer reviewed publications in the field of life sciences (molecular pharmacology, *in vitro* and *in vivo* pharmacology) and physical sciences (medicinal chemistry)

Patents

- An inventor to 7 patent families protecting new chemical entities, new indications and novel formulations

Hobbies and interest

- Running (marathon), hiking and down-hill skiing

Publications

- 1: Sallinen J, Höglund I, Engström M, Lehtimäki J, Virtanen R, Sirviö J, Wurster S, Savola JM, Haapalinna A. Pharmacological characterization and CNS effects of a novel highly selective alpha_{2C}-adrenoceptor antagonist JP-1302. *Br J Pharmacol*. 2007 Feb;150(4):391-402. Epub 2007 Jan 15. PubMed PMID: 17220913; PubMed Central PMCID: PMC2189732.
- 2: Höglund IP, Silver S, Engström MT, Salo H, Tauber A, Kyyrönen HK, Saarenketo P, Hoffrén AM, Kokko K, Pohjanoksa K, Sallinen J, Savola JM, Wurster S, Kallatsa OA. Structure-activity relationship of quinoline derivatives as potent and selective alpha_{2C}-adrenoceptor antagonists. *J Med Chem*. 2006 Oct 19;49(21):6351-63. PubMed PMID: 17034141.
- 3: Engström M, Savola JM, Wurster S. Differential efficacies of somatostatin receptor agonists for G-protein activation and desensitization of somatostatin receptor subtype 4-mediated responses. *J Pharmacol Exp Ther*. 2006 Mar;316(3):1262-8. Epub 2005 Nov 15. PubMed PMID: 16291731.
- 4: Engström M, Närvänen A, Savola JM, Wurster S. Assessing activation of the human neuropeptide FF2 receptor with a non-radioactive GTP binding assay. *Peptides*. 2004 Dec;25(12):2099-104. PubMed PMID: 15572197.
- 5: Engström M, Tomperi J, El-Darwish K, Ahman M, Savola JM, Wurster S. Superagonism at the human somatostatin receptor subtype 4. *J Pharmacol Exp Ther*. 2005 Jan;312(1):332-8. Epub 2004 Aug 27. PubMed PMID: 15333679.
- 6: Engström M, Wurster S, Savola JM, Panula P. Functional properties of Pfr(Tic)amide and BIBP3226 at human neuropeptide FF2 receptors. *Peptides*. 2003 Dec;24(12):1947-54. PubMed PMID: 15127947.
- 7: Peltonen JM, Nyrönen T, Wurster S, Pihlavisto M, Hoffrén AM, Marjamäki A, Xhaard H, Kanerva L, Savola JM, Johnson MS, Scheinin M. Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha_{2A}-adrenoceptor. *Br J Pharmacol*. 2003 Sep;140(2):347-58. Epub 2003 Aug 18. PubMed PMID: 12970108; PubMed Central PMCID: PMC1574035.
- 8: Römer L, Wurster S, Savola JM, Raasmaja A. Identification and characterization of the imidazoline I_{2b}-binding sites in the hamster brown adipose tissue as a study model for imidazoline receptors. *Arch Physiol Biochem*. 2003 Apr;111(2):159-66. PubMed PMID: 12919003.
- 9: Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brochie JM. Fipamezole (JP-1730) is a potent alpha₂ adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. *Mov Disord*. 2003 Aug;18(8):872-83. PubMed PMID: 12889076.
- 10: Engström M, Brandt A, Wurster S, Savola JM, Panula P. Prolactin releasing peptide has high affinity and efficacy at neuropeptide FF2 receptors. *J Pharmacol Exp Ther*. 2003 Jun;305(3):825-32. Epub 2003 Feb 20. PubMed PMID: 12606605.

- 11: Saleem A, Engström M, Wurster S, Savola JM, Pihlaja K. Interaction of folk medicinal plant extracts with human alpha2-adrenoceptor subtypes. *Z Naturforsch C*. 2002 Mar-Apr;57(3-4):332-8. PubMed PMID: 12064736.
- 12: Nyrönen T, Pihlavisto M, Peltonen JM, Hoffrén AM, Varis M, Salminen T, Wurster S, Marjamäki A, Kanerva L, Katainen E, Laaksonen L, Savola JM, Scheinin M, Johnson MS. Molecular mechanism for agonist-promoted alpha(2A)-adrenoceptor activation by norepinephrine and epinephrine. *Mol Pharmacol*. 2001 May;59(5):1343-54. PubMed PMID: 11306720.
- 13: Mustonen P, Savola J, Lassila R. Atipamezole, an imidazoline-type alpha(2)-adrenoceptor inhibitor, binds to human platelets and inhibits their adrenaline-induced aggregation more effectively than yohimbine. *Thromb Res*. 2000 Aug 1;99(3):231-7. PubMed PMID: 10942789.
- 14: Salminen T, Varis M, Nyrönen T, Pihlavisto M, Hoffrén AM, Lönnberg T, Marjamäki A, Frang H, Savola JM, Scheinin M, Johnson MS. Three-dimensional models of alpha(2A)-adrenergic receptor complexes provide a structural explanation for ligand binding. *J Biol Chem*. 1999 Aug 13;274(33):23405-13. PubMed PMID: 10438518.
- 15: Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM, Scheinin M. Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. *Eur J Pharmacol*. 1999 Jun 11;374(1):137-46. PubMed PMID: 10422650.
- 16: Jansson CC, Kukkonen JP, Näsman J, Huifang G, Wurster S, Virtanen R, Savola JM, Cockcroft V, Akerman KE. Protean agonism at alpha2A-adrenoceptors. *Mol Pharmacol*. 1998 May;53(5):963-8. PubMed PMID: 9584224.
- 17: Heinonen P, Koskua K, Pihlavisto M, Marjamäki A, Cockcroft V, Savola JM, Scheinin M, Lönnberg H. A series of 6-(omega-methanesulfonylthioalkoxy)-2-N-methyl- 1,2,3, 4-tetrahydroisoquinolines: cysteine-reactive molecular yardsticks for probing alpha2-adrenergic receptors. *Bioconjug Chem*. 1998 May-Jun;9(3):358-64. PubMed PMID: 9576810.
- 18: Marjamäki A, Pihlavisto M, Cockcroft V, Heinonen P, Savola JM, Scheinin M. Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human alpha2A-adrenergic receptor. *Mol Pharmacol*. 1998 Mar;53(3):370-6. PubMed PMID: 9495800.
- 19: Haapalinna A, Viitamaa T, MacDonald E, Savola JM, Tuomisto L, Virtanen R, Heinonen E. Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. *Naunyn Schmiedebergs Arch Pharmacol*. 1997 Nov;356(5):570-82. PubMed PMID: 9402036.
- 20: Kukkonen JP, Huifang G, Jansson CC, Wurster S, Cockcroft V, Savola JM, Akerman KE. Different apparent modes of inhibition of alpha2A-adrenoceptor by alpha2-adrenoceptor antagonists. *Eur J Pharmacol*. 1997 Sep 17;335(1):99-105. PubMed PMID: 9371550.
- 21: Pohjanoksa K, Jansson CC, Luomala K, Marjamäki A, Savola JM, Scheinin M. Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. *Eur J Pharmacol*. 1997 Sep 17;335(1):53-63. PubMed PMID: 9371546.

- 22: Savontaus E, Raasmaja A, Rouru J, Koulu M, Pesonen U, Virtanen R, Savola JM, Huupponen R. Anti-obesity effect of MPV-1743 A III, a novel imidazoline derivative, in genetic obesity. *Eur J Pharmacol.* 1997 Jun 11;328(2-3):207-15. PubMed PMID: 9218703.
- 23: Heinonen P.; Sipila H.; Neuvonen K.; Lonnberg H.1; Cockcroft V.; Wurster S.; Virtanen R.; Savola M.; Salonen J.; Savola J. Synthesis and pharmacological properties of 4(5)-(2-ethyl-2,3-dihydro-2-silainden-2-yl)imidazole, a silicon analogue of atipamezole. *European Journal of Medicinal Chemistry*, Volume 31, Number 9, 1996, pp. 725-729(5)
- 24: Savola MK, Savola JM. alpha 2A/D-Adrenoceptor subtype predominates also in the neonatal rat spinal cord. *Brain Res Dev Brain Res.* 1996 Jun 14;94(1):106-8. PubMed PMID: 8816283.
- 25: Savola MK, Savola JM. [3H]Dexmedetomidine, an alpha 2-adrenoceptor agonist, detects a novel imidazole binding site in adult rat spinal cord. *Eur J Pharmacol.* 1996 Jun 13;306(1-3):315-23. PubMed PMID: 8813646.
- 26: Vikman HL, Savola JM, Raasmaja A, Ohisalo JJ. Alpha 2A-adrenergic regulation of cyclic AMP accumulation and lipolysis in human omental and subcutaneous adipocytes. *Int J Obes Relat Metab Disord.* 1996 Feb;20(2):185-9. PubMed PMID: 8646256.
- 27: Jansson CC, Karp M, Oker-Blom C, Näsman J, Savola JM, Akerman KE. Two human alpha 2-adrenoceptor subtypes alpha 2A-C10 and alpha 2B-C2 expressed in Sf9 cells couple to transduction pathway resulting in opposite effects on cAMP production. *Eur J Pharmacol.* 1995 Jul 18;290(2):75-83. PubMed PMID: 8575536.
- 28: Sjöholm B, Savola JM, Scheinin M. Nonadrenergic binding of [3H]atipamezole in rat lung. A novel imidazole binding site? *Ann N Y Acad Sci.* 1995 Jul 12;763:66-77. PubMed PMID: 7677386.
- 29: Halme M, Sjöholm B, Savola JM, Scheinin M. Recombinant human alpha 2-adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 as radioligands. *Biochim Biophys Acta.* 1995 Apr 28;1266(2):207-14. PubMed PMID: 7742388.
- 30: Jansson CC, Savola JM, Akerman KE. Different sensitivity of alpha 2A-C10 and alpha 2C-C4 receptor subtypes in coupling to inhibition of cAMP accumulation. *Biochem Biophys Res Commun.* 1994 Mar 15;199(2):869-75. PubMed PMID: 7907869.
- 31: Jansson CC, Marjamäki A, Luomala K, Savola JM, Scheinin M, Akerman KE. Coupling of human alpha 2-adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells. *Eur J Pharmacol.* 1994 Jan 15;266(2):165-74. PubMed PMID: 7908883.
- 32: Oker-Blom C, Jansson C, Karp M, Lindqvist C, Savola JM, Vlak J, Akerman K. Functional analysis of the human alpha 2C-C4 adrenergic receptor in insect cells expressed by a luciferase-based baculovirus vector. *Biochim Biophys Acta.* 1993 Apr 16;1176(3):269-75. PubMed PMID: 8097112.
- 33: Sjöholm B, Voutilainen R, Luomala K, Savola JM, Scheinin M. Characterization of [3H]atipamezole as a radioligand for alpha 2-adrenoceptors. *Eur J Pharmacol.* 1992 Apr 29;215(1):109-17. PubMed PMID: 1355439.

- 34: Savola JM, Virtanen R. Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine. *Eur J Pharmacol.* 1991 Mar 26;195(2):193-9. PubMed PMID: 1678707.
- 35: Savola M, Savola JM, Puurunen J. Alpha 2-adrenoceptor-mediated inhibition of gastric acid secretion by medetomidine is efficiently antagonized by atipamezole in rats. *Arch Int Pharmacodyn Ther.* 1989 Sep-Oct;301:267-76. PubMed PMID: 2576195.
- 36: Savola JM. Cardiovascular actions of medetomidine and their reversal by atipamezole. *Acta Vet Scand Suppl.* 1989;85:39-47. PubMed PMID: 2571276.
- 37: Virtanen R, Savola JM, Saano V. Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole. *Arch Int Pharmacodyn Ther.* 1989 Jan-Feb;297:190-204. PubMed PMID: 2567152.
- 38: Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. *Eur J Pharmacol.* 1988 May 20;150(1-2):9-14. PubMed PMID: 2900154.
- 39: Savola JM, Ruskoaho H, Salonen JS, Puurunen J, Karjalainen A, Kurkela K, Kärki NT. Cardiovascular and sedative alpha-adrenoceptor effects of detomidine-like arylalkyl imidazoles and associated derivatives. *Arzneimittelforschung.* 1988 Jan;38(1):29-35. PubMed PMID: 2835056.
- 40: Savola JM. Alpha-adrenoceptor activity of arylalkylimidazoles is improved by alpha-methylation and impaired by alpha-hydroxylation. *Naunyn Schmiedeberg's Arch Pharmacol.* 1986 Dec;334(4):423-9. PubMed PMID: 2881218.
- 41: Savola JM, Ruskoaho H, Puurunen J, Salonen JS, Kärki NT. Evidence for medetomidine as a selective and potent agonist at alpha 2-adrenoreceptors. *J Auton Pharmacol.* 1986 Dec;6(4):275-84. PubMed PMID: 2880852.
- 42: Savola JM, Virtanen R, Karjalainen A, Ruskoaho H, Puurunen J, Kärki NT. Re-evaluation of drug-interaction with alpha-adrenoceptors in vivo and in vitro using imidazole derivatives. *Life Sci.* 1986 Apr 14;38(15):1409-15. PubMed PMID: 3007911.
- 43: Savola JM. Cardiovascular actions of detomidine. *Acta Vet Scand Suppl.* 1986;82:47-57. PubMed PMID: 3464182.
- 44: Savola JM, Ruskoaho H, Puurunen J, Kärki NT. Cardiovascular action of detomidine, a sedative and analgesic imidazole derivative with alpha-agonistic properties. *Eur J Pharmacol.* 1985 Nov 26;118(1-2):69-76. PubMed PMID: 2867913.
- 45: Savola JM, Puurunen J, Ruskoaho H, Kärki NT. Peripheral cardiovascular alpha- and beta-adrenergic effects of some hypotensive and bradycardic arylalkyl imidazole derivatives in the rat. *J Pharm Pharmacol.* 1985 Jun;37(6):410-4. PubMed PMID: 2862264.
- 46: Ruskoaho H, Savola JM, Kaipainen S, Puurunen J, Kärki N. The cardiovascular effects of MPV 295 [4(5)-2-(2,6-dimethylphenyl)ethylimidazole], a new antihypertensive agent with

alpha2-adrenoceptor agonistic properties. Naunyn Schmiedebergs Arch Pharmacol. 1983 May;322(4):279-85. PubMed PMID: 6135165.

47: Savola JM. Cardiovascular and sedative effects of novel detomidine-like arylalkyl imidazoles and related derivatives with special emphasis on pharmacological characterization of the alpha2-adrenoceptor. Acta Univ Ouluensis Series D Medica 147 1986.

Patents

1. Karl E. O. Akerman, Christian Jansson, Jyrki Kukkonen, Juha-Matti Savola, Siegfried Wurster, Victor Cockcroft. Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives ..., US Pat. 5994384 - Filed Sep 16, 1998 - Orion Corporation
2. Juha-Matti Savola, Paivi Juujarvi, Jukka Ilkka. Oromucosal formulation and process for preparing the same, US Pat. 10534091 - Filed Nov 10, 2003
3. Arto Karjalainen, Paavo Huhtala, Juha-Matti Savola, Siegfried Wurster, Maire Eloranta, Maarit Hillilä, Raimo Saxlund, Victor Cockcroft, Arja Karjalainen. Imidazole derivatives having affinity for alpha2 receptors, US Pat. 6313311 - Filed Feb 2, 1999 - Orion Corporation
4. Siegfried Wurster, Mia Engstrom, Juha-Matti Savola, Lisa Hoglund, Jukka Sallinen, Antti Haapalinna, Andrei Yurievitch Tauber, Anna-Marja Katariina Hoffren, Harri Elias Salo. Derivatives of quinoline as alpha-2 antagonists. US Pat. 9794277 - Filed Feb 28, 2001
5. Arto Karjalainen, Paavo Huhtala, Juha-Matti Savola, Siegfried Wurster, Maire Eloranta, Maarit Hillilä, Raimo Saxlund, Victor Cockcroft, Arja Karjalainen. Imidazole derivatives having affinity for a2-receptors. US Pat. 6479530 - Filed Jul 16, 2001 - Orion Corporation
6. Siegfried Wurster, Mia Engstrom, Juha-Matti Savola, Lisa Hoglund, Jukka Sallinen, Antti Haapalinna, Andrei Yurievitch Tauber, Anna-Marja Katariina Hoffren, Harri Elias Salo. Derivatives of quinoline as alpha-2 antagonists. US Pat. 10414474 - Filed Apr 16, 2003 - Orion Corporation, Oy Juvantia Pharma Ltd.
7. Antti Haapalinna, Timo Viitamaa, Jukka Sallinen, Mika Scheinin, Juha-Matti Savola. Method for the treatment of mental illness in mammals and a composition therefor. US Pat. 5902807 - Filed May 12, 1997
8. Heinonen Petri, Cockcroft Victor, Lönnberg Harri, Savola Juha-Matti. A method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives. US 6096752, Filed 1998-10-07: Juvantia Pharma Ltd